{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-25-000122","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.991569+00:00","generated_at":"2026-05-17T19:45:25.346820+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arcutis Q2 product revenue $81.5M (+164% YoY); ZORYVE foam approved for scalp/body psoriasis","bullets":["Net product revenue $81.5M vs $30.9M YoY, driven by ZORYVE portfolio demand across four approved indications.","Net loss narrowed to $15.9M ($0.13/sh) from $52.3M ($0.42/sh) YoY; cash $191.1M as of June 30.","ZORYVE foam 0.3% approved in May 2025 for scalp/body psoriasis; sales commenced in June.","PDUFA date Oct 13, 2025 for ZORYVE cream 0.05% in children 2–5 with atopic dermatitis.","IND submitted for ARQ-234 (CD200R agonist); halted ARQ-255 (alopecia areata) program."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-25-000122","json":"https://secwatch.observer/filing/0001787306-25-000122.json","markdown":"https://secwatch.observer/filing/0001787306-25-000122.md","text":"https://secwatch.observer/filing/0001787306-25-000122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000122/0001787306-25-000122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000122/arqt-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:45:25.346820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}